AAX Biotech and Daiichi Sankyo Advance Collaboration
Swedish biotech firm AAX Biotech AB and Japanese pharmaceutical company Daiichi Sankyo have moved into a new phase of their collaboration following an evaluation of AAX's Opti-mAb® technology.
Swedish biotechnology company AAX Biotech AB announced it has entered a new phase of collaboration with Japanese pharmaceutical firm Daiichi Sankyo. The companies have agreed to advance their partnership into an antibody program after an initial evaluation of AAX Biotech's proprietary Opti-mAb® technology.
The decision to proceed suggests that both parties see potential in the technology for developing next-generation antibody therapeutics. This expanded collaboration aims to explore the capabilities of AAX's Opti-mAb® platform in creating new therapeutic treatments.
AAX Biotech specializes in pioneering advanced technologies for the biotechnology sector. Daiichi Sankyo is a global healthcare company engaged in the research, development, manufacturing, and marketing of pharmaceuticals.
Financial terms of the expanded collaboration have not been disclosed. The advancement signifies a mutual interest in further investigating the technology's potential for novel drug development.